Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | MGLL | Q99685 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PHGDH | O43175 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115881 | 0.96 | CYP1A2 (0.64) | RAB9AMGLLCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5653105 | 0.86 | POLB (0.71) | FAAHMGLLCYP1A2CYP2D6KMT2A | |
| SCHEMBL18424173 | 0.83 | CYP1A2 (0.73) | FAAHMGLLCYP1A2CYP2D6KMT2A | |
| SCHEMBL26042174 | 0.83 | CYP1A2 (0.69) | FAAHMGLLCYP1A2CYP2D6KMT2A | |
| SCHEMBL29082478 | 0.82 | CYP1A2 (0.62) | RAB9AMGLLCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5649217 | 0.81 | HSD17B10 (0.81) | RAB9ACYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL640619 | 0.81 | CYP1A2 (0.76) | RAB9AFAAHMGLLCYP1A2CYP2D6 | |
| SCHEMBL3044836 | 0.81 | MAPT (0.69) | FAAHMGLLCYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL4599121 | 0.80 | ALDH1A1 (0.65) | RAB9AMGLLKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL3996605 | 0.79 | MGLL (0.63) | FAAHMGLLCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | claimed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | claimed |
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | RAB9A 2926/4885FAAH 474/4885MGLL 8/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | RAB9A 3386/4885FAAH 352/4885MGLL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.